Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions, today announced that members of its senior management team are scheduled to participate in two upcoming investor conferences.
Wells Fargo Securities 2018 Healthcare Conference
Date: Wednesday, September 4, 2019
Time: 3:35 p.m. ET
Location: The Westin Copley Place Hotel, Boston, MA
Citi’s 14th Annual Biotech Conference
Date: Thursday, September 5, 2019
Location: The Four Seasons Hotel, Boston, MA
About Karuna
Karuna is an innovative clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical need. Karuna is currently conducting a Phase 2 clinical trial of its lead product candidate, KarXT (Karuna-Xanomeline-Trospium), for the treatment of acute psychosis in patients with schizophrenia. Karuna also plans to initiate clinical trials of KarXT to evaluate its potential therapeutic benefit in other central nervous system disorders, including psychosis in Alzheimer’s disease, as well as pain.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190828005184/en/
Contacts
Investor Contact:
Chris Brinzey
Westwicke, an ICR Company
+1 339-970-2843
chris.brinzey@westwicke.com
Media Contact:
Liz Bryan
GlobalHealthPR
+1 202 587-2526
lbryan@globalhealthpr.com
Source: Karuna Therapeutics, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20190828005184/en
